1185237-08-4
Chemical Structure
rac-Fesoterodine-d14 fumarate
- CAS No.: 1185237-08-4
- Formula:C30H27D14NO7
- Molecular Weight:541.74
IUPAC Name: 2-(3-(bis(propan-2-yl-d7)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl isobutyrate fumarate
InChIKey: MWHXMIASLKXGBU-VCQPCXMRSA-N
SMILES: C(=CC(O)=O)C(O)=O.C(CCN(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])[2H])C(C([2H])([2H])[2H])(C([2H])([2H])[2H])[2H])(C1=C(OC(C(C)C)=O)C=CC(CO)=C1)C2=CC=CC=C2
Biological Activity: (Rac)-Fesoterodine-d14 fumarate is a labelled racemic Fesoterodine. Fesoterodine is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKivalues of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine is used for the overactive bladder (OAB)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
rac-Fesoterodine-d14 fumarate | (Rac)-Fesoterodine-d14 fumarate is a labelled racemic Fesoterodine. Fesoterodine is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKivalues of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine is used for the overactive bladder (OAB). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fesoterodine-d3 | Fesoterodine-d3 is the deuterium labeled Fesoterodine (HY-70053). Fesoterodine is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine is used for the overactive bladder (OAB). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fesoterodine | 99.61% | Fesoterodine is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine is used for the overactive bladder (OAB). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Ellsworth P, et al. Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag. 2009;5:869-76. Epub 2009 Nov 18. [Content Brief]
